Mainz Biomed (MYNZ) said Thursday it partnered with Quest Diagnostics (DGX) to support the commercialization of its NextGen screening test for colorectal cancer.
Under the agreement, the company said Quest will provide clinical trial laboratory services for its clinical trial involving about 15,000 participants across 150 US sites, adding that the study will generate data for FDA validation of the NextGen test.
The medical test maker also said it would offer Quest semi-exclusive rights to provide testing services using the ColoAlert kit for 18 months, contingent on FDA approval.
ColoAlert test is a stool-based test to detect colorectal cancer tumor DNA to help identify colorectal cancer in its early stages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.